**Name of journal: World Journal of Clinical Oncology**

**ESPS Manuscript NO: 8263**

**Columns: Topic Highlight**

WJCO 5th Anniversary Special Issues (2): Breast cancer

Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets

Rucci N *et al*. Bone metastasis from breast cancer

Nadia Rucci, Patrizia Sanità, Simona Delle Monache, Edoardo Alesse, Adriano Angelucci

**Nadia Rucci, Patrizia Sanità, Simona Delle Monache, Edoardo Alesse, Adriano Angelucci**

Department of Biotechnological and Applied Clinical Science, University of L’Aquila, Coppito 267100, L’Aquila, Italy

**Author contributions:** All authors contributed to this paper.

**Correspondence to: Adriano Angelucci, Professor,** Department of Biotechnological and Applied Clinical Science, University of L’Aquila, Via Vetoio, Coppito 267100, L’Aquila, Italy. adriano.angelucci@univaq.it

**Telephone:** +39-862-433550 **Fax**: +39-862-433523

**Received:** December 22, 2013 **Revised:** April 24, 2014

**Accepted:** May 28, 2014

**Published online:**

**Abstract**

Metastatic occurrence is the principal cause of death in breast cancer patients. The high osteotropism makes breast cancer the most common primary tumor type associated with metastatic bone disease. The peculiar clinical aspects associated with metastases limited to the skeletal system suggest considering these cases as a distinctive subset of metastatic patients with a better prognosis. Because bone is frequently the first metastatic site in disease relapse, it is feasible that the next improvement in therapeutic options for bone metastatic disease could be associated with an improvement of survival expectation and quality of life in breast cancer patients. Study of the molecular basis of bone remodeling and breast cancer osteotropism has allowed identification of several therapeutic candidates involved in formation and progression of bone metastases. These targets are frequently the determinants of positive feedback between the tumor and bone cells whose clinical outcome is osteolytic lesions. In this review, we discuss the physiopathologic features underlying targeted therapeutic strategies aimed at interfering with the aberrant bone remodeling associated with breast cancer metastases.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** breast cancer, bone metastasis, targeted therapy, osteoclasts, osteoblasts

**Core tip:** Breast cancer cells preferentially colonize bone sites during their metastatic diffusion. Bone microenvironment and tumor cells operate a reciprocal selective pressure that results in the formation of osteolytic lesion and tumor progression. Targeting the molecular factors involved in this interaction has been demonstrated to be an effective strategy in preventing the clinical morbidity associated with bone metastases. In this review, we summarize physiopathologic aspects of bone metastases from breast cancer and discuss the most promising therapeutic targets for their future clinical management.

Rucci N, Sanità P, Delle Monache S, Alesse E, Angelucci A. Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets. *World J Clin Oncol* 2014; In press

**Available from:**

**DOI:**

**CLINICAL ASPECTS**

Progress in the diagnosis and treatment of primary breast carcinoma (BrCa) has not led to an overall improvement in survival. The main reason is that residual disease always generates distant metastases, eventually leading to a substantial reduction in life expectancy. As revealed by autopsy studies, undiagnosed metastases in BrCa patients are more frequent than expected, and without an effective strategy aimed at reducing the spread of cancer cells, clinically relevant metastases are estimated to remain the main cause of death associated with BrCa. Although the presence of metastasis at diagnosis is uncommon in BrCa, the risk for this complication increases considerably within a few years after first treatment. Metastases involving multiple organs, mainly the lung, liver, and bone, are the most frequent situation, while the incidence of isolated metastasis is thought to be lower than 5%[[1](#_ENREF_1)].

Large autopsy series have demonstrated that bone metastases are present in 54%–73% of BrCa patients who died of the cancer[[2](#_ENREF_2)]. In addition, the high incidence of latent bone metastases at autopsy and the frequent detection of disseminated tumor cells in the bone marrow by sensitive methods suggest that bone colonization by BrCa cells is commonly associated with an indolent disease course and clinical dormancy[[3](#_ENREF_3)]. For this reason, study of the molecular determinants associated with predominance of dormancy over aggressive metastatic growth will have an important impact on clinical management of BrCa patients.

Although BrCa is the most common primary tumor type associated with metastatic bone disease, bone-only metastasis is infrequent and about 2% of these patients are diagnosed at the time of initial treatment[[4](#_ENREF_4),[5](#_ENREF_5)]. Also, according to autopsy records the chance of having bone-restricted metastasis is very low. Patients with disease confined to bone are more likely to be older at diagnosis and to have well differentiated tumors. Bone metastases are frequently associated with lung and/or liver metastases, and the cases with bone-only metastases are about 5%[[1](#_ENREF_1)]. In a distinctive way, patients with bone metastasis are more likely to have metastases in the central nervous system (CNS, about 27%) with respect to patients without bone metastasis (about 10%)[[6](#_ENREF_6)], and 18% of patients with CNS disease have bone as the initial site[[7](#_ENREF_7)]. In addition, lung and liver metastases are frequently found in more widespread disease with respect to bone metastasis[[6](#_ENREF_6)].

The predilection of BrCa cells for bone is confirmed by the fact that in more than 50% of BrCa patients, bone is the first site of distant relapse[[5](#_ENREF_5),[8](#_ENREF_8)]. The median period from BrCa diagnosis to the development of first metastatic bone lesion is about 3 years. However, 49% of these relapsing patients tend to develop extraosseous metastases, and 56% of patients with solitary bone metastasis tend to develop multiple metastatic bone lesions.

Also, for BrCa patients with bone-only disease the presence of multiple bone metastases at first diagnosis is common (59%), and the more frequent (> 50%) anatomical sites are thoracic and lumbar spine, the sternum, and pelvis. The sternum was described as the site of solitary metastasis in a significant percentage of BrCa patients at the time of diagnosis and this could be explained by anatomical proximity with the primary tumor[[5](#_ENREF_5),[9](#_ENREF_9)].

The median survival after the first recurrence of BrCa in bone is markedly higher with respect to the survival of those with first recurrence of cancer in extraosseous sites (20 mo *vs* 3 mo) [[8](#_ENREF_8)]. Although bone-only metastasis demonstrates a relative good prognosis, skeletal involvement is frequently associated with considerable morbidity. This includes hypercalcemia, fractures, impaired mobility, and spinal cord compression and pain, which require higher and higher doses of analgesics.

According to the histological and clinical features, bone metastases can be classified as osteolytic, osteosclerotic, or mixed, the latter when both features coexist in the same metastatic district [[10](#_ENREF_10)]. BrCa bone metastases are quite exclusively osteolytic, characterized by bone destruction due to an exacerbated activity of osteoclasts, the bone cells physiologically devoted to resorb bone matrix. Indeed, the first theories speculated that the osteolytic lesion was the result of physical pressure of the tumor on the bone or bone resorption activity of the tumor cells themselves. It has also been highlighted that cancer cells induce lymphocytes to produce factors such as prostaglandins, which in turn could stimulate destruction of the bone[[11](#_ENREF_11)]. To date, more and more evidence has conclusively shown that cancer cells are not able to directly destroy the bone, but they release factors that directly or indirectly activate the formation and activity of osteoclasts [[10](#_ENREF_10)].

Due to the prevalent osteolytic nature of BrCa bone metastasis, skeletal morbidity can now be predicted by the measurement of specific biochemical markers derived from the breakdown of type I collagen[[12](#_ENREF_12)]. These peptides include crosslinked C-terminal telopeptide isomers (CTX) and crosslinked N-terminal telopeptide (NTX), which can be measured in serum and urine.

**MOLECULAR BASES**

The high osteotropism of BrCa cells has been widely demonstrated in preclinical studies. The predilection of tumor cells for bone tissue could not be explained simply by anatomical features, and the so-called “seed and soil” theory, postulated by Steven Paget more than 100 years ago, is still valid today[[13](#_ENREF_13)]. This theory emphasizes that the process of colonization requires an interaction between tumor cells, which represent the seed, and the bone microenvironment, a deposit of calcium and growth factors released in response to bone resorption that provides the fertile “soil” in which cancer cells can proliferate.

These considerations have supported an intense investigation of the molecular determinants of osteotropism. However, the frequent widespread presentation of metastases in BrCa patients indicates that the pure osteotropic signature is restricted to a limited number of bone-only cases. Today, histologic analysis of BrCa subtypes drives prognosis, and in many cases permit prediction of the metastatic propensity of the primary tumor [[14](#_ENREF_14)]. Although much effort has been made to find a link between molecular profiles and metastatic site, this has not been fully established. In addition, molecular subtyping of the primary tumor is often not repeated in the metastases and the assumption that the metastatic tumor has identical marker expression as the primary tumor is currently debated[[15](#_ENREF_15)]. Moreover, it has to be considered that the bone microenvironment, with its peculiar characteristics, may exert strong selective pressure on tumor cells, thus influencing the resulting phenotype of clinically relevant metastases. For example, parathyroid hormone-related protein (PTHrP), which was previously considered an effective predictor for identifying patients who are at high risk of developing bone metastases and which is expressed in the large majority of BrCa bone metastases and in 60% of primary BrCa, is thought to be stimulated in BrCa cells in response to trasforming growth factor-β (TGF-β) released in the bone[[16](#_ENREF_16)].

Estrogen receptor (ER) expression represents the best consolidated marker associated with the risk for bone metastasis[[17](#_ENREF_17)]. ER+ breast tumors relapse preferentially to the bones over a delayed period[[18](#_ENREF_18)]. However, because there is significant loss of ER expression at many metastatic sites including bone, the role of ER in driving pathogenesis of bone metastasis needs to be verified[[6](#_ENREF_6)].

**THERAPEUTIC OPTIONS**

Bone-only metastatic cases have attracted clinical attention due to their good response to treatment and their association with extended patient survival. This aspect suggests considering patients diagnosed with metastases limited to the skeletal system as a distinctive subset of metastatic BrCa patients. The median survival of patients with metastatic BrCa involving extraskeletal sites is significantly shorter with respect to that of patients with bone-only metastasis, independent of the number of sites of skeletal involvement[[19](#_ENREF_19)]. Over the past two decades, bisphosphonates have emerged as a safe and effective component of treatment of bone metastatic disease from different cancers. The use of bisphosphonates in managing bone metastases had a profound beneficial effect on the frequency and severity of skeletal morbidity, resulting in improvement of quality of life[[20](#_ENREF_20)]. Bisphosphonates are potent inhibitors of osteoclast function that are recommended for long-term treatment[[21](#_ENREF_21)]. These compounds bind to exposed bone mineral and then are internalized by bone-resorbing osteoclasts, inhibiting bone resorption with different modes of action. Nitrogen-containing bisphosphonates (*e.g.*, zoledronic acid and pamidronate) act by inhibiting farnesyl diphosphate synthase, while other bisphosphonates are involved in the formation of cytotoxic metabolites in osteoclasts[[22](#_ENREF_22),[23](#_ENREF_23)]. In addition, recent studies have suggested that bisphosphonates may directly affect tumor cell invasion and survival [[24](#_ENREF_24)] and inhibit tumor-induced angiogenesis[[25](#_ENREF_25)].

Beyond the use of bisphosphonates, considered the most effective treatment for cancer-induced skeletal complications, other therapy choices include orthopedic intervention, radiation therapy, and cyclooxygenase-2 inhibitors or nonsteroidal anti-inflammatory drugs for reducing bone pain[[26](#_ENREF_26)]. Novel agents in clinical development are bone-seeking radionuclides that have been demonstrated to be safe and potentially useful in combination therapy with bisphosphonates or radiosensitizing drugs[[27](#_ENREF_27)].

**PHYSIOLOGY OF BONE REMODELING**

Understanding the molecular mechanisms leading to cancer-induced bone metastases requires knowledge of the physiology of bone tissue which, in contrast to its “hard” feature, is extremely dynamic and undergoes continuous renewal throughout the life of each individual, through a process known as bone remodeling [[28](#_ENREF_28)]. In particular, it has been estimated that about 10% of the bone is renewed every year [[29](#_ENREF_29)]. This phenomenon guarantees the following crucial functions: (1) Regulation of calcium homeostasis; (2) Renewal of old bone; (3) Substitution of primary infantile bone with mechanically competent bone; and (4) Repair of ischemic and microfractured bone.

Bone remodeling is the result of a perfect balance between the function of bone resorption performed by osteoclasts and osteogenesis accomplished by osteoblasts. Both cell types are the principal cells of bone tissue. This balance is crucial for maintenance of a proper bone mass and the lack of synchrony between the two functions is the starting point for skeletal diseases. As described in Figure 1, bone remodeling takes place according to the following phases:

***Activation phase***

This phase is so called because the lining cells, which are quiescent osteoblasts, respond to different stimuli (*i.e.*, growth factors, alteration of mechanical loading, and micro fractures) by increasing the expression of factors that stimulate osteoclast differentiation.

***Resorption phase***

Mature osteoclasts polarize on the bone surface, adhere to it and, by a process of acidification and subsequent release of proteolytic enzymes, such as the cathepsin K and the metalloproteinase (MMP)-9, degrade the bone matrix[[30](#_ENREF_30)].Once they have accomplished their function, osteoclasts undergo apoptosis, a physiologic consequence necessary to avoid exacerbated bone resorption.

***Reverse phase***

This phase is so called because of the presence of reverse cells, macrophage-like cells that are likely responsible for removing the debris produced during bone matrix degradation.

***Formation phase***

The players of this phase are osteoblasts, recruited by the growth factors that are usually stored in the bone matrix but that are released after its degradation by osteoclasts. Once recruited, osteoblasts produce a new bone matrix, initially not calcified (osteoid), and then they provide mineralization, thus completing the bone remodeling process.

**THE PLAYERS IN BONE REMODELING**

The principal cells of the bone involved in bone remodeling, osteoblasts and osteoclasts, also play a key role in the development of bone metastases.

***Osteoclast formation and function***

Osteoclasts arise from the monocyte/macrophage lineage[[31](#_ENREF_31)] and are multinucleated cells formed by the fusion of mononuclear precursors[[30](#_ENREF_30)]. Starting from a pluripotent hematopoietic stem cell, the transcription factor PU.1, along with macrophage colony stimulating factor (M-CSF), drives the commitment of a common progenitor for macrophages and osteoclasts. In particular, M-CSF stimulates proliferation of osteoclast precursors and upregulates receptor activator of nuclear factor kappa-B(RANK) expression, while PU.1 positively regulates the expression of c-Fms, the M-CSF receptor [[32](#_ENREF_32)]. With the appearance of c-Fms and RANK receptors, the precursors become fully committed to an osteoclast lineage. The RANK/receptor activator of nuclear factor kappa-B ligand (RANKL) pathway is mandatory for osteoclast differentiation and function, although it is not the only player in correct osteoclastogenesis.

Once differentiated, multinucleated osteoclasts need to adhere to the bone matrix and polarize in order to resorb bone. The first step of resorption requires the dissolution of the inorganic component of the matrix, which is hydroxyapatite. This can be achieved by the release of hydrochloric acid into the area to be resorbed, called resorption lacuna[[33](#_ENREF_33)], and also requires sealing of the underlined bone matrix, which is achieved through a cytoskeletal rearrangement and subsequent formation of an actin ring. This is a circumferential structure formed by several dynamic and dot-like structures called podosomes, each of which consists of an actin core surrounded by the v3 integrin and associated cytoskeletal proteins [[34](#_ENREF_34)].

Dissolution of mineral crystals allows digestion of the bone matrix organic component, which is performed by MMPs and lysosomial cathepsins. Among the latter, cathepsin K has a crucial role, as its deletion in mice leads to several skeletal diseases[[35](#_ENREF_35)]. Regarding the MMPs, osteoclasts mainly produce the MMP-9 isoform and, to a lesser extent, MMP-14[[36](#_ENREF_36)].

***Osteoblasts***

They arise from a mesenchymal stem cell (MSC) lineage consisting of pluripotent cells following a specific program of gene expression that may give rise to different tissue-specific cells including osteoblasts, chondrocytes, fibroblasts, myocytes, and adipocytes [[37](#_ENREF_37)]. The initial step of osteoblastogenesis is the commitment of MSCs towards an osteo/chondro-progenitor, which relies on the activation of two principal pathways: the Wingless-int (Wnt) pathway and the pathway triggered by bone morphogenetic proteins (BMPs). One of the earliest factors mandatory for osteoblast differentiation is Runt-related transcription factor 2 (RUNX2), along with osterix (OSX), which is downstream of RUNX2[[38](#_ENREF_38)]. Committed pre-osteoblasts are identifiable because they express alkaline phosphatase (ALP), one of the earliest markers of the osteoblast phenotype. As the pre-osteoblasts cease to proliferate, a key signaling event occurs for development of the large cuboidal differentiated osteoblasts. The active osteoblast is highly enriched in ALP and secretes bone matrix proteins such as collagen I and several non-collagenous proteins including osteocalcin, osteopontin, osteonectin, and bone sialoprotein II.

**REGULATION OF BONE REMODELING**

Several factors, systemic as well as local, regulate bone remodeling. Moreover, it is well known that the two principal players of bone remodeling talk to each other to reciprocally regulate their functions. In particular, osteoblasts produce RANKL mainly in the transmembrane form and, to a lesser extent, as soluble cytokine, which interacts with its receptor RANK, expressed by osteoclast precursors, eventually activating the intracellular pathway that stimulates osteoclast differentiation[[39](#_ENREF_39)]. Osteoblasts also produce osteoprotegerin (OPG), a soluble protein with the same extracellular structure as RANK but lacking the transmembrane domain. This allows it to act as a decoy receptor, since it binds RANKL, thus preventing its interaction with RANK and inhibiting osteoclastogenesis. Therefore, osteoclast differentiation relies on a proper RANKL/OPG ratio [[40](#_ENREF_40)].

**BONE REMODELING PERTURBATION AND THE ONSET OF THE VICIOUS CYCLE**

The physiology of bone remodeling is drastically disrupted by tumor cells once they colonize the bone milieu, eventually leading to the so-called vicious cycle (Figure 2). Indeed, tumor cells produce factors that, directly or indirectly through osteoblasts, induce exacerbated osteoclastogenesis, which in turn increases bone resorption and osteolysis. This means that tumor cells are not able to destroy bone per se, but they constrain resident cells to support their growth by creating new spaces inside the bone and allowing the release of several growth factors stored herein, such TGF-β, VEGF, insulin-like growth factors, platelet-derived growth factor, and BMPs. Thus, synergy between osteoclasts and tumor cells is created that fuels the vicious cycle, with an inexorable increase in both bone destruction and tumor growth [[10](#_ENREF_10)].

The ability of tumor cells to release in the bone microenvironment osteoclastogenic factors, usually produced by osteoblasts, further feeds the vicious cycle. Among the osteoclastogenic factors is PTHrP, produced by tumor cells under the stimulation of TGF-β, which in turn elicits RANKL expression and inhibits OPG production by bone marrow stromal cells and osteoblasts. Evidence for a role of PTHrP in this context arose some years ago from studies by Theresa Guise showing, in a mouse model of bone metastasis, that treatment with PTHrP-blocking antibody reduced BrCa cell-induced osteolysis as well as cancer growth. Moreover, tumor cells also produce M-CSF and prostaglandin E2, as well as several pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, IL-11, and Tumor Necrosis Factor α (TNFα), which directly stimulate osteoclast formation and function[[41](#_ENREF_41)]. Finally, evidence from the vicious cycle tells us that, in order to fight it, we could act on two fronts: interfering with the release of specific factors by tumor cells or inhibiting aberrant osteoclastogenesis, and these two phenomena are strictly related.

**THERAPEUTIC TARGETS**

***RANK/RANKL pathway***

Given the crucial role of this pathway in osteoclast differentiation, it is not surprising that it has been considered one of the most promising therapeutic targets, leading to the development of denosumab, a human monoclonal antibody directed against membrane-bound and soluble RANKL. Denosumab prevents the binding of RANKL to its receptor, eventually leading to the inhibition of osteoclastogenesis. This drug is currently in clinical trials for the treatment of post-menopausal osteoporosis and bone metastases. In particular, denosumab administered subcutaneously every 4 wk at a dose of 120 mg showed a higher efficiency compared with zoledronic acid in delaying the onset of skeletal-related events in patients with BrCa and in reducing the levels of the bone resorption marker NTX[[42](#_ENREF_42)]. However, there was no difference between the two drugs in terms of the effect on patient survival. With regard to the potential side effects, we should not forget the role played by RANKL in the immunologic contest. A few cases of osteonecrosis of the jaw[[43](#_ENREF_43)] as well as frequent occurrence of hypocalcaemia[[44](#_ENREF_44)] have been reported.

***Cathepsin K***

Cathepsins are a family of cysteine proteases with 11 members in humans (cathepsin B, C, H, F, K, L, O, S, V, W, and X/Z) with different functions, such as antigen presentation, apoptosis, and autophagy. In the pathological context, cathepsin has been positively correlated with tumour invasion and angiogenesis[[45](#_ENREF_45)]. Indeed, B and L cathepsins are prognostic markers of different cancers, among them breast, where their increased expression is associated with a poor prognosis[[46](#_ENREF_46)].

Among the different cathepsins, the K isoform has been identified as a good therapeutic target in bone metastasis treatment, due to its pivotal role in bone resorption. Recently, inhibition of cathepsin B was also proven to be effective at inhibiting bone and lung metastases in a mouse model of BrCa[[47](#_ENREF_47)]. The crucial role of cathepsin K in osteoclast functions has been clarified by the evidence that a human mutant form of this gene determines a rare genetic disease called pycnodysostosis, characterized by an impairment of bone resorption. Preclinical data from animal models of BrCa bone metastases showed the ability of the cathespin K inhibitor AFG-495 to reduce osteolytic lesions as well as local tumour growth[[48](#_ENREF_48)]. Another recent compound is odanacatib (MK-0822), a promising drug already used for osteoporosis treatment. A phase II clinical trial involving BrCa patients with bone metastases showed a reduction of bone resorption markers after 4 wk of treatment[[49](#_ENREF_49)].

***Metalloproteases***

Due to their function of degrading extracellular matrix, MMPs are obviouslyinvolved in the general process of invasion and metastasis. Indeed, some of them play a specific role in the onset of bone metastases, such as MMP-7, which is able to cut membrane-bound RANKL, thus increasing its local activity and favoring bone metastasis development[[50](#_ENREF_50)]. MMP-1, along with a disintegrin-like and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), promotes proteolytic cleavage of epidermal growth factors (EGFs), which in turn inhibit osteoblast production of OPG, thus favoring osteoclastogenesis[[51](#_ENREF_51)]. Nannuru *et al*[[52](#_ENREF_52)] showed that treatment of mice with Cl66 mammary tumors with MMP13 antisense oligonucleotides led to a significant reduction in bone destruction and in the number of activated osteoclasts at the tumor-bone interface, likely by reducing MMP-9 and RANKL expression.

***Vascular cell adhesion proteins***

This family is also mainly involved in carcinogenesis and metastasis. Among them, vascular cell adhesion proteins (VCAMs) seem to give a specific contribution to the development of bone metastases, as demonstrated by a recent study. Indeed, by interacting with its integrin receptor41, VCAM-1 promotes the recruitment of osteoclast precursors. Moreover, treatment of metastatic mice with VCAM-1-blocking antibody significantly reduced bone and lung metastases [[53](#_ENREF_53)].

***Mammalian target of rapamycin***

Rapamycin is an immunosuppressive and antitumoral drug previously used to prevent graft rejection. Rapamycin inhibits mammalian target of rapamycin (mTOR), which is a serine-threonine kinase that stimulates cell survival and proliferation and whose deregulation is associated with the development of several tumors. What makes rapamycin an interesting target for bone metastases treatment is the evidence that the signal triggered by mTOR is important for the survival of osteoclasts[[54](#_ENREF_54)]. Moreover, a recent study showed that treatment with rapamycin reduced both the incidence and the area of the osteolytic lesion, through the inhibition of osteoclast formation[[55](#_ENREF_55)].

***Integrins***

Integrins include a large family of surface receptors that mediate cell-extracellular matrix interactions. Osteoclasts mainly express v3 integrin, which plays a crucial role in osteoclast adhesion, a process that is mandatory for correct bone resorption[[56](#_ENREF_56)]. Preclinical evidence shows that v3 inhibition blocks osteolysis and tumor growth in animal models of bone metastases. These studies were the starting point for ongoing clinical trials that are testing the effectiveness of various v3 antagonists in different bone metastatic cancers [[57](#_ENREF_57)].

***Erythroblastic leukemia viral oncogene homolog (ErbB) receptors***

TheErbB family of receptor tyrosine kinases represents an attractive therapeutic target in carcinomas. In fact, ErbB kinases are frequently overexpressed in these cancers and regulate important aspects of cancer progression by activating several key intracellular signaling intermediates, including PhosphoInositide 3 Kinase (PI3K), Ras-Raf Mitogen Activated Protein Kinase (MAPK), c-Jun N-terminal Kinase (JNK) and PhosphoLipase C (PLC)[[58](#_ENREF_58)].The ErbB family comprises four members: ErbB1 [alias epidermal growth factor receptor (EGFR) and HER1]; ErbB2 (alias HER2 and Neu); ErbB3 (alias HER3); and ErbB4 (alias HER4). For EGFR and HER2, sufficient data have been collected to support their use as two of the five protein surrogate markers for assessing BrCa subtypes [ER, progesterone receptor (PgR), HER2, EGFR, and cytokeratin-5 (CK5)] [[59](#_ENREF_59)]. The role of the other ErbB kinases in BrCa progression remains controversial. In addition, only HER2 is found to be amplified in about 25% of primary BrCa cases. Although the data indicate that EGFR is not overexpressed in primary BrCa with respect to the normal breast epithelia[[60](#_ENREF_60)], recent studies have suggested a significant association of EGFR expression with the aggressive basal-type BrCa[[61](#_ENREF_61)] and with circulating BrCa cells[[62](#_ENREF_62),[63](#_ENREF_63)].

Current evidence does not support the hypothesis that EGFR or HER2 expression can predict bone metastasis[[17](#_ENREF_17)]. In contrast, ErbB-expressing BrCa shows the predilection to metastasize to visceral sites, including the brain, liver, and lung[[64](#_ENREF_64)]. Nevertheless, numerous preclinical studies have proposed a leading role for ErbB kinases in the progression of bone metastases[[65](#_ENREF_65)]. In particular, ErbB receptors may participate in the positive feedback underlying the vicious cycle. In fact, EGFR ligands present in the bone microenvironment are able to directly stimulate bone cells and osteolysis. Among the recognised ligands of the ErbB family, EGF, TGF-β, and amphiregulin (AREG) have been proposed as the main players in the bone microenvironment. EGF and TGF-β stimulation of osteoclastogenesis and bone resorption is accompanied by decreased OPG expression and sustained production of RANKL by bone stromal cells[[56](#_ENREF_56),[66](#_ENREF_66)]. In addition, EGFR is expressed by osteoblasts, and its activation stimulates osteoblast proliferation and decreases mineralization[[67](#_ENREF_67)]. EGFR ligands may also function by an autocrine loop, stimulating the release of cytokines by BrCa cells that directly influence osteoclastogenesis or indirectly stimulating EGFR signaling within bone cells. The key cytokine produced by BrCa cells in this way is PTHrP, which is able to stimulate RANKL expression and inhibit OPG expression in cells of the osteoblast lineage[[68](#_ENREF_68)]. In addition, PTHrP induces the expression and shedding of AREG and TGF-β, increasing the availability of ErbB ligands in the bone microenvironment. In turn, osteoblasts release EGFR ligands and perpetuate the cycle of osteoclast activation via RANKL and thus bone destruction [[65](#_ENREF_65)].

***Src***

In the last few years, Src, a nonreceptor tyrosine kinase, has attracted increasing interest due to its involvement in both tumorigenesis and bone metabolism. Src activity appears to be significantly associated with the development of bone metastases and late-onset relapse to bone. Using a bioinformatics approach, it was demonstrated that the role of Src was independent of the distinct molecular subtypes of human BrCa and also ER status[[69](#_ENREF_69)].

In BrCa cells, Src is frequently overexpressed and overactivated, allowing the transduction of signaling pathways associated with proliferation, adhesion, invasion, and angiogenesis[[70](#_ENREF_70)]. In particular, Src is a key mediator for several cell surface receptors, including EGFR and HER2[[71](#_ENREF_71)]. Src-overexpressing tumors may have a specific survival advantage in the bone microenvironment. In fact, activated Src is required for Chemokine (C-X-C) motif Ligand 12 (CXCL12)/Stromal cell-Derived Factor (SDF)-mediated cell survival and abrogates TNF-Related Apoptosis-Inducing Ligand (TRAIL)-mediated apoptosis[[69](#_ENREF_69)]. Preclinical studies confirmed that treatment with Src inhibitors effectively reduced BrCa growth compared with untreated cells[[72](#_ENREF_72)]. In several mouse models of BrCa, inhibition of Src activity decreased metastases and improved survival[[73](#_ENREF_73),[74](#_ENREF_74)]. Other *in vivo* studies have found inhibition of bone metastasis but not of metastases at visceral sites, confirming the specific role for Src in bone turnover[[69](#_ENREF_69)]. Moreover, Src activity has been linked to resistance to anti-hormonal therapy[[75](#_ENREF_75)]. That BrCa bone metastases are more frequent in ER+ than ER- tumors suggests the possibility that Src inhibition could overcome resistance to endocrine therapy and block metastatic growth. The results from a clinical trial recruiting ER+ and HER2+ BrCa seemed to confirm a better potential activity of an inhibitor of Src in ER+ tumors with respect to HER2+ cases[[76](#_ENREF_76)].

At the same time, Src is a key signaling molecule in the physiology of bone, since osteoclast function appears to be dependent on the activation of Src[[77](#_ENREF_77)]. Indeed, src-deficient mice develop osteopetrosis, with a significant reduction of bone resorption, although the number of osteoclasts was equal to that of wild-type (WT) littermates, thus indicating that Src is mandatory for osteoclast activity[[78](#_ENREF_78)]. Significantly, when Src inhibitors were used in *in vivo* models of BrCa bone metastasis, it was reported that bone resorption as well as BrCa growth at the metastatic site were significantly inhibited[[74](#_ENREF_74)]. There are currently several Src inhibitors in preclinical development or in clinical trials for the treatment of solid tumors[[79](#_ENREF_79)]. One of these compounds, dasatinib, a dual Src/Abl inhibitor, approved for the treatment of leukemia, was successfully investigated in phase I/II clinical trials in patients with prostate and BrCa bone metastases. Dasatinib treatment was associated with a substantial decrease in bone resorption markers and with a lack of disease progression in a significant percentage of breast and prostate cancer patients[[80](#_ENREF_80),[81](#_ENREF_81)]. However, although recent data of the Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration Resistant Prostate Cancer (READY) trial confirmed the reduction in bone resorption, they showed no overall survival improvement, suggesting the need for appropriate predictive biomarkers[[82](#_ENREF_82)].

***Chemokines***

Chemokines constitute a family of small secreted cytokines. Their name comes from their ability to induce chemotaxis in adjacent responsive cells. Chemokines are generally divided into four classes according to the number and position of cysteine residues: CC, in which the residues are adjacent; CXC, in which the residues are separated by one amino acid; the family XC, which has only one cysteine residue; and CX3C, in which the cysteine residues are separated by three amino acids[[83](#_ENREF_83)]. Some chemokines are pro-inflammatory, being able to induce an immune response consisting of attraction of immune cells at the site of infection, while others are involved in homeostasis, controlling the process of cell migration. These proteins exert their effect by interacting with specific transmembrane receptors called chemokine receptors, present on many different cell types[[84](#_ENREF_84)]. The chemokine receptors belong to the family of G protein-coupled receptors (GPCRs), which have an extracellular region that binds to chemokines, seven transmembrane α-helices, and a cytoplasmic side associated with a G protein. Several studies highlighted the importance of CXCL12 (SDF-1) and CXCR4 in BrCa. The first studies on the role of CXCR4 in BrCa date back to 2001[[85](#_ENREF_85)], and its specific involvement in the migration of BrCa cells from the primary site through the basement membrane was reported by Yagi *et al*[[86](#_ENREF_86)] in 2011. Mutation at the COOH-terminal domain of CXCR4 also plays a role in receptor regulation during the process of epithelial-to mesenchymal transition[[87](#_ENREF_87)]. It has also been shown that CXCR4 levels are high in bone metastasis, suggesting that the CXCL12/CXCR4 axis plays an important role in its pathogenesis. CXCL12 is a homeostatic chemokine constitutively expressed also in those organs that are the most common metastatic sites of BrCa, including bone marrow, but its secretion by damaged tissues is particularly abundant. CXCR4 expression is low or absent in normal breast tissue, while it is upregulated in neoplastic tissue; moreover, CXCR4 levels are related to the degree of tumor malignancy. However, additional studies are needed to confirm that the increase of CXCR4 expression can be a predictive marker for metastatic diffusion. Shim *et al*[[88](#_ENREF_88)] showed that, in cultured cells, the binding of CXCL12 to CXCR4 induced CXCR4 translocation from the cytoplasm to the nucleus. After its translocation to the nucleus, CXCR4 works as a transcription factor[[89](#_ENREF_89)], leading to upregulation of cytokines such as MCP-1 and IL-8 and metalloproteases such as MMP-2 and MMP-9. The importance of CXCR4 in BrCa progression was confirmed by the use of anti-CXCR4 antibody or specific siRNA, in vitro and in vivo, showing its ability to block the formation and the dissemination of metastasis.

Given the involvement of chemokines and chemokine receptors in tumor progression, many molecules have been developed to counteract their biological activity. These molecules belong to two categories: peptides and small molecules. Bicyclams are low-molecular-weight agents that have been shown to act as potent and selective CXCR4 antagonists. Bicyclam AMD 3100 (Plerixafor) is currently being investigated in clinical trials alone or in combination with bisphosphonates[[83](#_ENREF_83)]. The 14-residue polypeptide 4F-benzoyl-TN14003 (BKT140) is a highly selective and unique CXCR4 antagonist[[90](#_ENREF_90)]. Besides its ability to inhibit BrCa metastases by impairing migration, it could also be used as a diagnostic tool to identify CXCR4 receptor-positive tumor cells in culture as well as in paraffin-embedded clinical tumor samples[[91](#_ENREF_91)]. Finally, in vivo studies have demonstrated that the synthetic peptide antagonist CTCE-9908 is able to reduce the incidence and extent of bone metastases. Unfortunately, results from the first clinical trials conducted in patients with advanced metastatic disease showed good tolerance but low response[[92](#_ENREF_92)].

***Transcription factors***

The osteolytic phenotype is associated with the activity of a specific pattern of transcription factors, including glioma-associated oncogene family zinc finger 2 (GLI2), RUNX2, and hypoxia-inducible factor-1 (HIF-1). In particular, GLI2 stimulates PTHrP expression by tumor cells and is mainly involved in the development of melanoma-induced bone metastases[[93](#_ENREF_93),[94](#_ENREF_94)]. With regard to RUNX2, it has been demonstrated that inactivating mutations of its gene in BrCa cells significantly inhibit bone metastasis development in animal models[[95](#_ENREF_95)]. Finally, HIF-1, besides its pivotal role in hypoxia-associated tumor progression, also stimulates tumour-driven osteolysis (Figure 3). Transcriptional activity of HIF-1 is induced by the reduction in oxygen (O2) availability. HIF-1 is a heterodimeric protein composed of an O2-regulated HIF-1α subunit and a constitutively expressed HIF-1β subunit[[96](#_ENREF_96)]. HIF proteins, when stabilized, trigger the transcription of numerous target genes involved in tumor growth and in promoting the feed-forward of the metastatic cycle[[97](#_ENREF_97)]. Hypoxia is a frequent consequence of the growth of solid tumors. It is well known that many hypoxia-response genes regulated by HIF-1α are genes involved in controlling energy metabolism. These include VEGF, which permits increased O2 delivery to cells by stimulating angiogenesis, and glycolytic enzymes, which allow cells to survive O2 deprivation[[98](#_ENREF_98)]. Paradoxically, therapeutic inhibition of tumor-induced angiogenesis could stimulate autocrine growth factor secretion downstream of HIF-1, thus producing a more aggressive phenotype in BrCa cell lines[[99](#_ENREF_99)].

Concerning the role of hypoxia in pre-metastatic niche formation, clinical studies have shown that expression levels of HIF-1α in BrCa patients increase proportionally with the severity of the pathologic stage[[100](#_ENREF_100)]. As reported by Le *et al*[[101](#_ENREF_101)] in 13 different types of human cancers, HIF-1α was overexpressed in two-thirds of the all regional lymph nodes and bone metastasis examined. Furthermore, increased levels of HIF-1α were associated with a poor prognosis[[102](#_ENREF_102),[103](#_ENREF_103)]. Several data have indicated that factors stimulated by HIF-1α are associated with bone metastasis through their capacity to modify extracellular bone matrix and stimulate metastatic homing of cancer cells[[85](#_ENREF_85),[104](#_ENREF_104),[105](#_ENREF_105)].

Some of the most well-known target genes of hypoxia, which are able to promote metastatic progression, include lysyl oxidase (LOX), LOX-like (LOXL) family proteins such as LOXL2 and LOXL4, TGF-β, MMP2, MMP9, CXCR4, SDF-1, and VEGF[[106](#_ENREF_106)]. It was demonstrated that HIF-1, in hypoxic BrCa cells, could promote BrCa metastasis by inducing the expression of LOX proteins. This phenomenon is probably due to increased VEGF secretion by endothelial cells (ECs) and the modification of collagen molecules in the extracellular matrix (ECM)[[107](#_ENREF_107)]. While the role of LOX in metastases was initially attributed to its capacity to remodel the ECM in the proximity of the primary tumor, subsequent studies revealed that LOX could remodel the ECM at distant sites and recruit bone marrow-derived cells to the metastatic niche[[108](#_ENREF_108)].

In the bone microenvironment, overactivated HIF-1α can increase the development of osteolytic bone metastases *via* dysregulation of factors involved in the vicious cycle. Several findings have suggested that acidosis, which is caused by glycolytic metabolism of hypoxic cancer cells, has a negative effect on osteoblast differentiation as well as on osteoblast functions[[109](#_ENREF_109),[110](#_ENREF_110)]. In contrast to the effect on osteoblast differentiation, hypoxia seems to stimulate osteoclast-like cell formation. Frick *et al*[[111](#_ENREF_111)] demonstrated higher RANKL mRNA expression in bone cells caused by metabolic acidosis with respect to control. In addition, osteoblasts express components of the HIF-1 pathway, and hypoxia can upregulate the expression of VEGF-A, the major inducer of tumor angiogenesis[[112](#_ENREF_112)].

Although HIF-1 is an attractive therapeutic target and several different strategies have been developed to directly target HIF-1, none of these inhibitors have been translated to the clinical setting. However, different chemical compounds and chemotherapeutic drugs that indirectly target HIF-1α, such as EGFR inhibitors, digoxin and other cardiac glycosides, antracyclines, geldanamycin and other heat shock protein 90 (HSP90) inhibitors and, recently, topotecan and topoisomerase I inhibitors, have been shown to counteract primary cancer progression, angiogenesis, and metastasis in mouse models[[113-117](#_ENREF_113)]. Among these inhibitors, promising results were obtained with the HIF-1α inhibitor 2-methoxyestradiol (2ME2), which was able to decrease osteolytic lesion area and tumor burden in an in vivo model of bone metastasis[[118](#_ENREF_118), [119](#_ENREF_119)].

**CONCLUSION**

Bone represents a peculiar distant site for dissemination of BrCa cells: it is actively colonized and frequently becomes a fertile “soil” for tumor growth after the development of self-reinforcing crosstalk between tumor and bone cells. This interaction determines osteolysis and the consequent extensive morbidity, but it is also fundamental for cancer progression. Several preclinical and clinical data have demonstrated that the therapeutic strategy directed at interrupting the crosstalk between cancer and bone cells is effective in ameliorating prognosis. Therefore, understanding the effects of the factors implicated in physiopathology of bone remodeling may help to identify future targets for a curative therapy of bone metastasis.

**REFERENCES**

1 **Viadana E**, Bross ID, Pickren JW. An autopsy study of some routes of dissemination of cancer of the breast. *Br J Cancer* 1973; **27**: 336-340 [PMID: 4701705]

2 **Angelucci A,** Edoardo Alesse M. Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy. Biotargets of Cancer in Current Clinical Practice: Springer, 2012: 469-515

3 **Pantel K**, Alix-Panabières C, Riethdorf S. Cancer micrometastases. *Nat Rev Clin Oncol* 2009; **6**: 339-351 [PMID: 19399023 DOI: 10.1038/nrclinonc.2009.44]

4 **Li S**, Peng Y, Weinhandl ED, Blaes AH, Cetin K, Chia VM, Stryker S, Pinzone JJ, Acquavella JF, Arneson TJ. Estimated number of prevalent cases of metastatic bone disease in the US adult population. *Clin Epidemiol* 2012; **4**: 87-93 [PMID: 22570568 DOI: 10.2147/CLEP.S28339]

5 **Koizumi M**, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. *Ann Oncol* 2003; **14**: 1234-1240 [PMID: 12881385]

6 **Cummings MC**, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L, O'Rourke P, Lakhani SR. Metastatic progression of breast cancer: insights from 50 years of autopsies. *J Pathol* 2014; **232**: 23-31 [PMID: 24122263 DOI: 10.1002/path.4288]

7 **Altundag K,** Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. *Cancer* 2007; **110:** 2640-7 [PMID: 17960791 DOI: 10.1002/cncr.23088]

8 **Coleman RE**, Rubens RD. The clinical course of bone metastases from breast cancer. *Br J Cancer* 1987; **55**: 61-66 [PMID: 3814476]

9 **Kwai AH**, Stomper PC, Kaplan WD. Clinical significance of isolated scintigraphic sternal lesions in patients with breast cancer. *J Nucl Med* 1988; **29**: 324-328 [PMID: 3346742]

10 **Roodman GD**. Mechanisms of bone metastasis. *Discov Med* 2004; **4**: 144-148 [PMID: 20704976]

11 **Raisz LG**, Sandberg AL, Goodson JM, Simmons HA, Mergenhagen SE. Complement-dependent stimulation of prostaglandin synthesis and bone resorption. *Science* 1974; **185**: 789-791 [PMID: 4843377]

12 **Brown JE**, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. *Br J Cancer* 2003; **89**: 2031-2037 [PMID: 14647134 DOI: 10.1038/sj.bjc.66014376601437]

13 **Paget S**. The distribution of secondary growths in cancer of the breast. 1889. *Cancer Metastasis Rev* 1989; **8**: 98-101 [PMID: 2673568 DOI: 10.1016/S0140-6736(00)49915-0]

14 **Sørlie T**, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 2001; **98**: 10869-10874 [PMID: 11553815 DOI: 10.1073/pnas.19136709898/19/10869]

15 **St Romain P**, Madan R, Tawfik OW, Damjanov I, Fan F. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. *Hum Pathol* 2012; **43**: 398-404 [PMID: 21840040 DOI: 10.1016/j.humpath.2011.05.009S0046-8177(11)00219-X]

16 **Yin JJ**, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. *J Clin Invest* 1999; **103**: 197-206 [PMID: 9916131 DOI: 10.1172/JCI3523]

17 **Sihto H**, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. *Breast Cancer Res* 2011; **13**: R87 [PMID: 21914172 DOI: 10.1186/bcr2944]

18 **Schmidt-Kittler O**, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. *Proc Natl Acad Sci U S A* 2003; **100**: 7737-7742 [PMID: 12808139 DOI: 10.1073/pnas.13319311001331931100]

19 **Sherry MM**, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. *Am J Med* 1986; **81**: 381-386 [PMID: 2428242]

20 **Coleman RE**. Bisphosphonates: clinical experience. *Oncologist* 2004; **9 Suppl 4**: 14-27 [PMID: 15459426 DOI: 10.1634/theoncologist.9-90004-149/suppl\_4/14]

21 **Hillner BE**, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003; **21**: 4042-4057 [PMID: 12963702 DOI: 10.1200/JCO.2003.08.017JCO.2003.08.017]

22 **Rogers MJ**. New insights into the molecular mechanisms of action of bisphosphonates. *Curr Pharm Des* 2003; **9**: 2643-2658 [PMID: 14529538]

23 **Roelofs AJ**, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. *Clin Cancer Res* 2006; **12**: 6222s-6230s [PMID: 17062705]

24 **Clézardin P**, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. *Cancer Res* 2005; **65**: 4971-4974 [PMID: 15958534]

25 **Bezzi M**, Hasmim M, Bieler G, Dormond O, Rüegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. *J Biol Chem* 2003; **278**: 43603-43614 [PMID: 12933798 DOI: 10.1074/jbc.M308114200M308114200]

26 **Grond S**, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. *Pain* 1999; **79**: 15-20 [PMID: 9928771]

27 **Nilsson S**, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. *Clin Cancer Res* 2005; **11**: 4451-4459 [PMID: 15958630]

28 **Del Fattore A**, Teti A, Rucci N. Bone cells and the mechanisms of bone remodelling. *Front Biosci (Elite Ed)* 2012; **4**: 2302-2321 [PMID: 22202038]

29 **Zaidi M**. Skeletal remodeling in health and disease. *Nat Med* 2007; **13**: 791-801 [PMID: 17618270]

30 **Teitelbaum SL**. Osteoclasts: what do they do and how do they do it? *Am J Pathol* 2007; **170**: 427-435 [PMID: 17255310]

31 **Walker DG**. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. *Science* 1975; **190**: 784-785 [PMID: 1105786]

32 **Arai F**, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. *J Exp Med* 1999; **190**: 1741-1754 [PMID: 10601350]

33 **Baron R**, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. *J Cell Biol* 1985; **101**: 2210-2222 [PMID: 3905822]

34 **Teti A**, Marchisio PC, Zallone AZ. Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity. *Am J Physiol* 1991; **261**: C1-C7 [PMID: 1858848]

35 **Gelb BD**, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. *Science* 1996; **273**: 1236-1238 [PMID: 8703060]

36 **Andersen TL**, del Carmen Ovejero M, Kirkegaard T, Lenhard T, Foged NT, Delaissé JM. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. *Bone* 2004; **35**: 1107-1119 [PMID: 15542036]

37 **Grigoriadis AE**, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. *J Cell Biol* 1988; **106**: 2139-2151 [PMID: 3384856]

38 **Ducy P**, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. *Genes Dev* 1999; **13**: 1025-1036 [PMID: 10215629]

39 **Boyle WJ**, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003; **423**: 337-342 [PMID: 12748652 DOI: 10.1038/nature01658nature01658]

40 **Simonet WS**, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 1997; **89**: 309-319 [PMID: 9108485]

41 **Weilbaecher KN**, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. *Nat Rev Cancer* 2011; **11**: 411-425 [PMID: 21593787 DOI: 10.1038/nrc3055nrc3055]

42 **Lipton A**, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. *J Clin Oncol* 2007; **25**: 4431-4437 [PMID: 17785705]

43 **Stopeck AT**, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010; **28**: 5132-5139 [PMID: 21060033 DOI: 10.1200/JCO.2010.29.7101JCO.2010.29.7101]

44 **Henry DH**, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011; **29**: 1125-1132 [PMID: 21343556 DOI: 10.1200/JCO.2010.31.3304JCO.2010.31.3304]

45 **Vasiljeva O**, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. *Curr Pharm Des* 2007; **13**: 387-403 [PMID: 17311556]

46 **Nouh MA**, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM, Sloane BF. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. *J Transl Med* 2011; **9**: 1 [PMID: 21199580 DOI: 10.1186/1479-5876-9-11479-5876-9-1]

47 **Withana NP**, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS. Cathepsin B inhibition limits bone metastasis in breast cancer. *Cancer Res* 2012; **72**: 1199-1209 [PMID: 22266111 DOI: 10.1158/0008-5472.CAN-11-27590008-5472.CAN-11-2759]

48 **Le Gall C**, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. *Cancer Res* 2007; **67**: 9894-9902 [PMID: 17942921 DOI: 67/20/9894]

49 **Jensen AB**, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A, Lombardi A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. *Clin Breast Cancer* 2010; **10**: 452-458 [PMID: 21147688 DOI: 10.3816/CBC.2010.n.059S1526-8209(11)70193-8]

50 **Lynch CC**, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. *Cancer Cell* 2005; **7**: 485-496 [PMID: 15894268]

51 **Lu X**, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massagué J, Kang Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. *Genes Dev* 2009; **23**: 1882-1894 [PMID: 19608765 DOI: 10.1101/gad.1824809gad.1824809]

52 **Nannuru KC**, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. *Cancer Res* 2010; **70**: 3494-3504 [PMID: 20406980 DOI: 10.1158/0008-5472.CAN-09-32510008-5472.CAN-09-3251]

53 **Lu X**, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massagué J, Kang Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. *Cancer Cell* 2011; **20**: 701-714 [PMID: 22137794 DOI: 10.1016/j.ccr.2011.11.002S1535-6108(11)00408-9]

54 **Glantschnig H**, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. *Cell Death Differ* 2003; **10**: 1165-1177 [PMID: 14502240 DOI: 10.1038/sj.cdd.44012854401285]

55 **Hussein O**, Tiedemann K, Murshed M, Komarova SV. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. *Cancer Lett* 2012; **314**: 176-184 [PMID: 22014409 DOI: 10.1016/j.canlet.2011.09.026S0304-3835(11)00572-6]

56 **Zou W**, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. *J Cell Biol* 2007; **176**: 877-888 [PMID: 17353363 DOI: jcb.200611083]

57 **Clézardin P**. Therapeutic targets for bone metastases in breast cancer. *Breast Cancer Res* 2011; **13**: 207 [PMID: 21586099 DOI: 10.1186/bcr2835bcr2835]

58 **Angelucci A**. Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties. *Curr Cancer Drug Targets* 2009; **9**: 1-18 [PMID: 19200048]

59 **Carey LA**, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA* 2006; **295**: 2492-2502 [PMID: 16757721 DOI: 295/21/2492]

60 **Pawlowski V**, Révillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. *Clin Cancer Res* 2000; **6**: 4217-4225 [PMID: 11106235]

61 **Burness ML**, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? *Cancer J* 2010; **16**: 23-32 [PMID: 20164687 DOI: 10.1097/PPO.0b013e3181d24fc1]

62 **Braun S**, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmüller G, Pantel K. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. *Cancer Res* 2001; **61**: 1890-1895 [PMID: 11280743]

63 **Pantel K**, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmüller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. *J Natl Cancer Inst* 1993; **85**: 1419-1424 [PMID: 7688814]

64 **Eccles SA**, Welch DR. Metastasis: recent discoveries and novel treatment strategies. *Lancet* 2007; **369**: 1742-1757 [PMID: 17512859]

65 **Foley J**, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ. EGFR signaling in breast cancer: bad to the bone. *Semin Cell Dev Biol* 2010; **21**: 951-960 [PMID: 20813200 DOI: 10.1016/j.semcdb.2010.08.009S1084-9521(10)00146-1]

66 **Normanno N**, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R, Pinto A. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. *Endocr Relat Cancer* 2005; **12**: 471-482 [PMID: 15947117 DOI: 12/2/471]

67 **Qin L**, Partridge NC. Stimulation of amphiregulin expression in osteoblastic cells by parathyroid hormone requires the protein kinase A and cAMP response element-binding protein signaling pathway. *J Cell Biochem* 2005; **96**: 632-640 [PMID: 16088955 DOI: 10.1002/jcb.20550]

68 **Gilmore JL**, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ, Foley J. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. *Breast Cancer Res Treat* 2008; **110**: 493-505 [PMID: 17882547 DOI: 10.1007/s10549-007-9748-8]

69 **Zhang XH**, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. *Cancer Cell* 2009; **16**: 67-78 [PMID: 19573813 DOI: 10.1016/j.ccr.2009.05.017S1535-6108(09)00179-2]

70 **Thomas SM**, Brugge JS. Cellular functions regulated by Src family kinases. *Annu Rev Cell Dev Biol* 1997; **13**: 513-609 [PMID: 9442882 DOI: 10.1146/annurev.cellbio.13.1.513]

71 **Nautiyal J**, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. *Cancer Lett* 2009; **283**: 143-151 [PMID: 19398150 DOI: 10.1016/j.canlet.2009.03.035S0304-3835(09)00227-4]

72 **Jallal H**, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. *Cancer Res* 2007; **67**: 1580-1588 [PMID: 17308097]

73 **Myoui A**, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. *Cancer Res* 2003; **63**: 5028-5033 [PMID: 12941830]

74 **Rucci N**, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. *J Pharmacol Exp Ther* 2006; **318**: 161-172 [PMID: 16627750 DOI: jpet.106.102004]

75 **Varricchio L**, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M, Giovannelli P, Farrar W, Appella E, Auricchio F. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide. *Mol Cancer Res* 2007; **5**: 1213-1221 [PMID: 18025264]

76 **Mayer EL**, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. *Clin Cancer Res* 2011; **17**: 6897-6904 [PMID: 21903773 DOI: 10.1158/1078-0432.ccr-11-0070]

77 **de Vries TJ**, Mullender MG, van Duin MA, Semeins CM, James N, Green TP, Everts V, Klein-Nulend J. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. *Mol Cancer Res* 2009; **7**: 476-488 [PMID: 19372577 DOI: 10.1158/1541-7786.MCR-08-02197/4/476]

78 **Soriano P**, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. *Cell* 1991; **64**: 693-702 [PMID: 1997203 DOI: 0092-8674(91)90499-O]

79 **Zhang S**, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. *Trends Pharmacol Sci* 2012; **33**: 122-128 [PMID: 22153719 DOI: 10.1016/j.tips.2011.11.002S0165-6147(11)00208-2]

80 **Yu EY**, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. *Urology* 2011; **77**: 1166-1171 [PMID: 21539969 DOI: 10.1016/j.urology.2011.01.006S0090-4295(11)00024-0]

81 **Takahashi S**, Miyazaki M, Okamoto I, Ito Y, Ueda K, Seriu T, Nakagawa K, Hatake K. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. *Cancer Sci* 2011; **102**: 2058-2064 [PMID: 21781226 DOI: 10.1111/j.1349-7006.2011.02041.x]

82 **Araujo JC**, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. *Cancer* 2012; **118**: 63-71 [PMID: 21976132 DOI: 10.1002/cncr.26204]

83 **Teicher BA**, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. *Clin Cancer Res* 2010; **16**: 2927-2931 [PMID: 20484021 DOI: 10.1158/1078-0432.CCR-09-23291078-0432.CCR-09-2329]

84 **Fernandez EJ**, Lolis E. Structure, function, and inhibition of chemokines. *Annu Rev Pharmacol Toxicol* 2002; **42**: 469-499 [PMID: 11807180 DOI: 10.1146/annurev.pharmtox.42.091901.11583842/1/469]

85 **Müller A**, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. *Nature* 2001; **410**: 50-56 [PMID: 11242036 DOI: 10.1038/3506501635065016]

86 **Yagi H**, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, Gutkind JS. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Sci Signal* 2011; **4**: ra60 [PMID: 21934106 DOI: 10.1126/scisignal.20022214/191/ra60]

87 **Ueda Y**, Neel NF, Schutyser E, Raman D, Richmond A. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. *Cancer Res* 2006; **66**: 5665-5675 [PMID: 16740704]

88 **Shim H**, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. *Biochem Biophys Res Commun* 2006; **346**: 252-258 [PMID: 16756955]

89 **Huang YC**, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. *Biochem Pharmacol* 2007; **74**: 1702-1712 [PMID: 17904532]

90 **Wang J**, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. *Cancer Metastasis Rev* 2006; **25**: 573-587 [PMID: 17165132 DOI: 10.1007/s10555-006-9019-x]

91 **Tamamura H**, Sugioka M, Odagaki Y, Omagari A, Kan Y, Oishi S, Nakashima H, Yamamoto N, Peiper SC, Hamanaka N, Otaka A, Fujii N. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. *Bioorg Med Chem Lett* 2001; **11**: 359-362 [PMID: 11212110 DOI: 10.1016/S0960-894X(00)00664-8]

92 **Richert MM**, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. *Oncol Rep* 2009; **21**: 761-767 [PMID: 19212637]

93 **Sterling JA**, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M, Mundy GR. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. *Cancer Res* 2006; **66**: 7548-7553 [PMID: 16885353]

94 **Alexaki VI**, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A. GLI2-mediated melanoma invasion and metastasis. *J Natl Cancer Inst* 2010; **102**: 1148-1159 [PMID: 20660365 DOI: 10.1093/jnci/djq257djq257]

95 **Javed A**, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. *Proc Natl Acad Sci U S A* 2005; **102**: 1454-1459 [PMID: 15665096]

96 **Weidemann A**, Johnson RS. Biology of HIF-1alpha. *Cell Death Differ* 2008; **15**: 621-627 [PMID: 18259201 DOI: 10.1038/cdd.2008.12cdd200812]

97 **Harris AL**. Hypoxia--a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002; **2**: 38-47 [PMID: 11902584 DOI: 10.1038/nrc704]

98 **Wang Y**, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* 2005; **365**: 671-679 [PMID: 15721472]

99 **Voss MJ**, Möller MF, Powe DG, Niggemann B, Zänker KS, Entschladen F. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. *BMC Cancer* 2011; **11**: 158 [PMID: 21535870 DOI: 10.1186/1471-2407-11-1581471-2407-11-158]

100 **Bos R**, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. *J Natl Cancer Inst* 2001; **93**: 309-314 [PMID: 11181778]

101 **Le QT**, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. *Cancer Metastasis Rev* ; **23**: 293-310 [PMID: 15197330 DOI: 10.1023/B: CANC.0000031768.89246.d75273266]

102 **Gruber G**, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? *Breast Cancer Res* 2004; **6**: R191-R198 [PMID: 15084243 DOI: 10.1186/bcr775bcr775]

103 **Schindl M**, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. *Clin Cancer Res* 2002; **8**: 1831-1837 [PMID: 12060624]

104 **Kovacic N**, Croucher PI, McDonald MM. Signaling between tumor cells and the host bone marrow microenvironment. *Calcif Tissue Int* 2014; **94**: 125-139 [PMID: 24046000 DOI: 10.1007/s00223-013-9794-7]

105 **Owens P**, Polikowsky H, Pickup MW, Gorska AE, Jovanovic B, Shaw AK, Novitskiy SV, Hong CC, Moses HL. Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion. *PLoS One* 2013; **8**: e67533 [PMID: 23840733 DOI: 10.1371/journal.pone.0067533PONE-D-13-03284]

106 **Sceneay J**, Smyth MJ, Möller A. The pre-metastatic niche: finding common ground. *Cancer Metastasis Rev* 2013; **32**: 449-464 [PMID: 23636348 DOI: 10.1007/s10555-013-9420-1]

107 **Baker AM**, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, Reynolds AR, Cox TR, Erler JT. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. *Cancer Res* 2013; **73**: 583-594 [PMID: 23188504 DOI: 10.1158/0008-5472.CAN-12-24470008-5472.CAN-12-2447]

108 **Wong CC**, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, Semenza GL. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. *J Mol Med (Berl)* 2012; **90**: 803-815 [PMID: 22231744 DOI: 10.1007/s00109-011-0855-y]

109 **Tuncay OC**, Ho D, Barker MK. Oxygen tension regulates osteoblast function. *Am J Orthod Dentofacial Orthop* 1994; **105**: 457-463 [PMID: 8166095]

110 **Hiraga T**, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. *Cancer Res* 2007; **67**: 4157-4163 [PMID: 17483326]

111 **Frick KK**, Bushinsky DA. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. *J Bone Miner Res* 2003; **18**: 1317-1325 [PMID: 12854843 DOI: 10.1359/jbmr.2003.18.7.1317]

112 **Steinbrech DS**, Mehrara BJ, Saadeh PB, Greenwald JA, Spector JA, Gittes GK, Longaker MT. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. *Am J Physiol Cell Physiol* 2000; **278**: C853-C860 [PMID: 10751333]

113 **Lee K**, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. *Proc Natl Acad Sci U S A* 2009; **106**: 2353-2358 [PMID: 19168635 DOI: 10.1073/pnas.08128011060812801106]

114 **Zhang H**, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. *Proc Natl Acad Sci U S A* 2008; **105**: 19579-19586 [PMID: 19020076 DOI: 10.1073/pnas.08097631050809763105]

115 **Isaacs JS**, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. *J Biol Chem* 2002; **277**: 29936-29944 [PMID: 12052835 DOI: 10.1074/jbc.M204733200M204733200]

116 **Kummar S**, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. *Clin Cancer Res* 2011; **17**: 5123-5131 [PMID: 21673063 DOI: 10.1158/1078-0432.CCR-11-06821078-0432.CCR-11-0682]

117 **Mimeault M**, Batra SK. Development of animal models underlining mechanistic connections between prostate inflammation and cancer. *World J Clin Oncol* 2013; **4**: 4-13 [PMID: 23539141 DOI: 10.5306/wjco.v4.i1.4]

118 **Dunn LK**, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. *PLoS One* 2009; **4**: e6896 [PMID: 19727403 DOI: 10.1371/journal.pone.0006896]

119 **Mabjeesh NJ**, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. *Cancer Cell* 2003; **3**: 363-375 [PMID: 12726862]

**P-Reviewer:** Wicha MS **S-Editor:** Song XX **L-Editor:** **E-Editor:**



**Figure 1 Phases of bone remodeling.** Starting from the quiescence phase,bone remodeling is triggered by different stimuli that lead to activation of lining cells, which increase surface expression of RANKL. This cytokine, by binding to its receptor RANK, promotes osteoclast differentiation (activation phase). Next, mature osteoclasts resorb bone (resorption phase), thus allowing the release of factors usually stored in the bone matrix (BMPs, TGF-β and FGFs) that recruit osteoblasts in the reabsorbed area. Once recruited, osteoblasts form the bone matrix and ensure its mineralization (formation phase), completing the bone remodeling process. BMPs: Bone morphogenetic proteins; TGF-β: Trasforming growth factor-β; FGFs: Fibroblast growth factor.



**Figure 2 Schematic representation of the vicious cycle.** Under physiologic conditions, osteoblasts produce factors that regulate osteoclastogenesis (RANKL/OPG). Mature osteoclasts erode the bone matrix, allowing the release of factors (IGF-1, BMPs, TGF-β, PDGF, and FGFs). Tumor cells perturb this homeostasis by producing factors (PTHrP, IL-6, TNFα, M-CSF, and PGE2) that favor osteoclastogenesis, with subsequent bone resorption and release of the growth factors stored in the bone matrix, which in turn enhance tumor growth. BMPs: Bone morphogenetic proteins; TGF-β: Trasforming growth factor-β; FGFs: Fibroblast growth factor; IGFs: Insulin-like growth factors; PDGF: Platelet-derived growth factor; M-CSF: Macrophage colony stimulating factor; PGE2: Prostaglandin E2.



**Figure 3 Potential pro-metastatic role of hypoxia in bone.** Hypoxia stimulates targeting of cancer cells to bone and facilitates their survival within the bone microenvironment. The presence of a hypoxic environment, further sustained by cancer growth, induces the secretion of hypoxia-inducible factors by cancer cells. These factors, in conjunction with parallel acidification of the microenvironment, are associated with osteoclastogenesis.